News >

Niraparib Takes Step Toward Chinese Approval for Frontline Maintenance in Ovarian Cancer

Jason M. Broderick
Published: Monday, Mar 16, 2020

Samantha Du, PhD, founder and chief executive officer of Zai Lab Limited

Samantha Du, PhD

The China National Medical Products Administration (NMPA) has accepted a supplemental New Drug Application (sNDA) for niraparib (Zejula) for use as a frontline maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication